IGHE and bullous pemphigoid: In particular, 75% of patients with bullous pemphigoid with increased serum baseline level of IgE anti-BP180-NC16A showed completed response to omalizumab as compared to 41% of those who did not have these autoantibodies (p = 0.01) [69].